
|Videos|March 25, 2021
Continuing the Success Story With TRK Inhibitors
Author(s)David S. Hong, MD
David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, reacts to the growing interest around identifying NTRK gene fusions in various solid tumor types and treating appropriate patients with oral TRK inhibitors.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5






































